Literature DB >> 17998675

Adjuvant radiation therapy in gall bladder cancers: 10 years experience at Tata Memorial Hospital.

Umesh M Mahantshetty1, S R Palled, R Engineer, G Homkar, S K Shrivastava, P J Shukla.   

Abstract

INTRODUCTION AND
PURPOSE: In gall bladder cancers, even after curative surgery, survivals are dismal and loco-regional failure accounts for 40-86%. Although these are considered radio-resistant, adjuvant radiation, with or without chemotherapy, has been tried to improve loco-regional control and overall survival rates. With an aim to evaluate the natural history of gall bladder cancers, role of radiation therapy (RT) and prognostication, a retrospective analysis was undertaken.
MATERIALS AND METHODS: Between 1991-2000, 60 patients with gall bladder cancer, treated with radical intent, were evaluated. Patients details including history, physical examination, liver function tests, ultrasonography of the abdomen and chest X-ray; and CT scan Abdomen if done, were noted. In patients who underwent surgery, surgical details, histopathology and pathological staging, were recorded. The details of post-operative adjuvant treatment, including radiation therapy details, as well as chemotherapeutic agents, number of cycles and type of infusion [bolus/infusion], were noted.
RESULTS: Sixty patients underwent surgery. On histopathological staging, 28 patients (46.5%) had stage II, 19 (32%) had stage III, 12 (20%) had stage-I and 1 patient had stage IV disease. Thirteen (21%) patents did not receive any adjuvant treatment, 32 (53%) patients received adjuvant RT alone, 8(14%) received post-operative CT+RT and 7 (12%) patients received CT alone. With a median follow-up of 18 months (12-124 months), 27 (45%) patients were disease free, 11 (19%) had local failures, 7 (11%) had loco-regional, 7 (11%) loco-regional+distant, 4 (7%) distant and 4 (7%) patients had local+distant failures. The Overall Disease Free Survival (DFS) and overall survival was 30% and 25%, at 5 years, respectively. Stage grouping ('P' = 0.007), Pathological T ('P' = 0.01) had significant impact on DFS on univariate analysis, where as histological grade ('P' = 0.06) showed trend towards significance.
CONCLUSION: Gall bladder cancers are aggressive and lethal. Early diagnosis and curative surgery, followed by appropriate adjuvant radiation therapy, may improve survivals, with no established consensus till date. Following curative surgery, pathological T stage and stage grouping, are the significant prognostic factors for outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17998675     DOI: 10.4103/0973-1482.25850

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  7 in total

1.  Outcomes of adjuvant chemoradiation and predictors of survival after extended cholecystectomy in gall bladder carcinoma: a single institution experience from an endemic region.

Authors:  S Agrawal; P K Gupta; N Rastogi; A Lawrence; N Kumari; K J Maria Das; R Saxena
Journal:  J Gastrointest Cancer       Date:  2015-03

Review 2.  Chemotherapy and targeted therapy for gall bladder cancer.

Authors:  Bhawna Sirohi; Ashish Singh; P Jagannath; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2014-06-03

3.  Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.

Authors:  Vikas Ostwal; Rohit Swami; Shraddha Patkar; Swaratika Majumdar; Mahesh Goel; Shaesta Mehta; Reena Engineer; Sarika Mandavkar; Suman Kumar; Anant Ramaswamy
Journal:  Med Oncol       Date:  2018-03-21       Impact factor: 3.064

4.  Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy.

Authors:  Suzy Kim; Kyubo Kim; Eui Kyu Chie; Sun Whe Kim; Yung-Jue Bang; Sung Whan Ha
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2011-08-31

Review 5.  Gastrointestinal cancers in India: Treatment perspective.

Authors:  Nikhil Suresh Ghadyalpatil; Chopra Supriya; Patil Prachi; Dsouza Ashwin; Saklani Avanish
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

6.  Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.

Authors:  Jing-Tao Zhang; Wei Sun; Wen-Zhong Zhang; Chun-Yan Ge; Zhong-Yan Liu; Ze-Ming Zhao; Xing-Sui Lu; Yue-Zu Fan
Journal:  BMC Cancer       Date:  2014-03-15       Impact factor: 4.430

7.  Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.

Authors:  Hui Wang; Wei Sun; Wen-Zhong Zhang; Chun-Yan Ge; Jing-Tao Zhang; Zhong-Yan Liu; Yue-Zu Fan
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.